XBiotech Inc
Company Profile
Business description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
stocks
Weekly earnings wrap: FMG, WDS, COL and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.70 | 7.30 | 0.08% |
| CAC 40 | 8,319.87 | 142.52 | -1.68% |
| DAX 40 | 26,367.24 | 81.28 | 0.31% |
| Dow JONES (US) | 53,569.44 | 105.56 | 0.20% |
| FTSE 100 | 10,792.54 | 85.58 | -0.79% |
| HKSE | 25,690.52 | 124.78 | 0.49% |
| NASDAQ | 26,541.35 | 411.15 | 1.57% |
| Nikkei 225 | 66,555.99 | 424.02 | 0.64% |
| NZX 50 Index | 13,835.68 | 44.37 | -0.32% |
| S&P 500 | 7,730.99 | 55.29 | 0.72% |
| S&P/ASX 200 | 9,064.60 | 13.30 | 0.15% |
| SSE Composite Index | 3,959.64 | 3.07 | 0.08% |